This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== 1970: In the Wake of Poseidon and Lizard === King Crimson spent 1970 in a state of flux with various line-up changes, thwarted tour plans, and difficulties in finding a satisfactory musical direction, while Fripp was learning and developing as a songwriter during the writing process of the next three albums. As well as guitar, Fripp took on keyboard duties, while Sinfield expanded his creative role to operating synthesizers. Following McDonald's and Giles's departure, Lake, unsure of the band's future without them, began discussions with Keith Emerson of the Nice about possibly forming a new band together. With Fripp and Sinfield planning the recording of the second King Crimson album, and Lake's position uncertain, the band's management booked Elton John to sing on the album, a decision cancelled by Fripp after he listened to John's then-only album, Empty Sky, and deemed his singing style to be not right for King Crimson. Lake agreed to stay with the band until Emerson had completed remaining commitments with the Nice, at which point he left to form Emerson, Lake & Palmer with Emerson and Carl Palmer of Atomic Rooster. On the resulting In the Wake of Poseidon album, Lake provided all the lead vocals except on "Cadence and Cascade", which featured Fripp's old school friend Gordon Haskell. The sessions also included Michael and Peter Giles on drums and bass respectively, saxophonist Mel Collins (formerly of the band Circus), and jazz pianist Keith Tippett. Upon its release in May 1970, In the Wake of Poseidon reached No. 4 in the UK and No. 31 in the US.
January 3, 2013: Decree establishing an interministerial mission for the protection of women against violence and the fight against human trafficking. January 3, 2013: Decree establishing the High Council for Gender Equality. January 31, 2013: Law repealing Law No. 2010-1127 of September 28, 2010, aimed at combating school absenteeism. May 17, 2013: Law on the election of departmental, municipal, and community councillors and modifying the electoral calendar. May 17, 2013: Law opening marriage to same-sex couples. June 19, 2013: National interprofessional agreement "Toward a policy of improving quality of life at work and professional equality." July 8, 2013: Orientation and programming law for the refoundation of the Republic's school system. July 22, 2013: Law on higher education and research, notably requiring gender parity in elections and appointments to governance bodies of institutions. August 2, 2013: Law on the election of senators, introducing measures to increase female representation. August 5, 2013: Law on various adjustments in justice according to EU law and France's international commitments. November 2013: Fourth interministerial plan for preventing and combating violence against women. December 2013: Bill on combating the prostitution system. December 27, 2013: Decree on the annual report on professional equality in the civil service. January 20, 2014: Law ensuring the future and fairness of the pension system. April 16, 2014: Decree on the responsibilities of the Minister for Women's Rights, Cities, Youth, and Sports.
== Classification == Metal complexes, also including all coordination compounds, include virtually all metal compounds. The study of "coordination chemistry" is the study of "inorganic chemistry" of all alkali and alkaline earth metals, transition metals, lanthanides, actinides, and metalloids. Thus, coordination chemistry is the chemistry of the majority of the periodic table. Metals and metal ions exist, in the condensed phases at least, only surrounded by ligands. The areas of coordination chemistry can be classified according to the nature of the ligands, in broad terms:
Sources: en.wikipedia.org
24296Cm + 42He → 24598Cf + 10n To identify and separate out the element, ion exchange and adsorption methods were undertaken. Only about 5,000 atoms of californium were produced in this experiment, and these atoms had a half-life of 44 minutes. The discoverers named the new element after the university and the state. This was a break from the convention used for elements 95 to 97, which drew inspiration from how the elements directly above them in the periodic table were named. However, the element directly above element 98 in the periodic table, dysprosium, has a name that means "hard to get at", so the researchers decided to set aside the informal naming convention. They added that "the best we can do is to point out [that] ... searchers a century ago found it difficult to get to California". Weighable amounts of californium were first produced by the irradiation of plutonium targets at Materials Testing Reactor at National Reactor Testing Station, eastern Idaho; these findings were reported in 1954. The high spontaneous fission rate of californium-252 was observed in these samples. The first experiment with californium in concentrated form occurred in 1958. The isotopes 249Cf to 252Cf were isolated that same year from a sample of plutonium-239 that had been irradiated with neutrons in a nuclear reactor for five years.
=== Mixing with other insulins === The American Diabetes Association said in 2003 that, unlike some other longer-acting insulins, glargine should not be diluted or mixed with other insulin or solution in the same syringe, due to the low pH of its diluent. However, a 2004 study found that mixing glargine with other insulins did not affect short-term glycemic profile.
==== 2009 ==== In January 2009, Krasnaya Zvezda published an interview with Father Mikhail, the Orthodox priest, who said: "I attended military exercise "Kavkaz-2008" in South Ossetia, where our paratroopers worked out the skills of combat in the mountains. Unfortunately, those skills became useful too soon..." In late January 2009, Russian sergeant Aleksandr Glukhov ran away from Akhalgori District and requested a political asylum in Tbilisi. He had served in the 693rd regiment and he declared that he was deployed to South Ossetia in July 2008. In May 2009, Rossiyskaya Gazeta reported that hero of Russia, Denis Vetchinov, who died in South Ossetia, left the base of the Motor Rifle Division in Vladikavkaz for Tskhinvali on the early morning of 7 August 2008. In June 2009, Russian General Vyacheslav Borisov told Echo of Moscow in an interview: "I headed the South Ossetian and the Georgian directions. You know, we even regularly hold exercises in those areas. And our troops had full practice by holding exercises one week before right there in the same place. And we had only concluded and went." In July 2009, Russian journalist Ella Polyakova wrote that some Russian soldiers had told her that they arrived in South Ossetia on 4 August 2008, while their records claimed that they were stationed in North Ossetia. In July 2009, Russian blogger published an interview with soldier Maksim Belyaev, who said: "Our combined battalion of peacekeepers was stationed in North Ossetia. We should have replaced in August another battalion of the peacekeeping mission, located in Tskhinvali.
James L. Winkle College of Pharmacy Linder College of Business - Masters in Business Administration College of Allied Health - Masters in Health Administration The programs are organized as preparation for leadership in settings such as independent and chain community pharmacies, health-system inpatient, outpatient and clinical pharmacies, clinical coordinator roles, managed care, industry, long-term care.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.